Welcome to our dedicated page for Curis news (Ticker: CRIS), a resource for investors and traders seeking the latest updates and insights on Curis stock.
Curis Inc. (NASDAQ: CRIS) is a biotechnology company dedicated to the development and commercialization of groundbreaking drug candidates aimed at treating human cancers. Established as a significant player in the biotech sector, Curis is renowned for its focus on immuno-oncology and precision oncology therapeutic areas.
Core Business and Pipeline
Curis's pipeline is robust, featuring a number of promising drug candidates. One of its leading drugs is Emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor currently undergoing clinical trials. The trials include the Phase 1/2 TakeAim Lymphoma study, which targets hematologic malignancies such as non-Hodgkin's lymphoma, and the Phase 1/2 TakeAim Leukemia study aimed at acute myeloid leukemia and myelodysplastic syndrome. Emavusertib has already received Orphan Drug Designation from the U.S. Food and Drug Administration.
Curis is also investigating other candidates such as CUDC-907, which focuses on relapsed or refractory diffuse large B-cell lymphoma with alterations in the MYC oncogene, and other small molecule antagonists like CA-170 and CA-327, designed to inhibit pathways such as PD1, VISTA, and TIM3.
Collaborations & Partnerships
Curis has forged a strategic collaboration with Aurigene, granting it exclusive licenses to several promising molecules. This partnership enhances Curis's ability to innovate in the areas of immuno-oncology and precision oncology, specifically with oral small molecule antagonists. Additionally, Curis has licensed its rights to Erivedge® to Genentech, which is commercializing the drug for advanced basal cell carcinoma under the Roche Group.
Recent Achievements and Financial Condition
Curis has recently presented data from multiple clinical studies at prestigious conferences such as the American Society of Hematology (ASH) and the European Hematology Association (EHA), showcasing promising results from its ongoing trials. The company reported a net loss of $47.4 million for the year ended December 31, 2023, but continues to maintain a strong cash position with $56.3 million in cash, cash equivalents, and investments.
Curis's ongoing research and development efforts are backed by substantial funding and strategic partnerships, enabling the company to sustain its operations and advance its pipeline into the year 2025.
For more information, visit Curis's website at www.curis.com.
Curis, Inc. (NASDAQ: CRIS) announced the FDA's approval to resume patient enrollment in the monotherapy phase of its TakeAim Leukemia study. Previously, this study faced a partial hold that the FDA imposed in April 2022 due to safety concerns related to rhabdomyolysis. After reviewing additional data, the FDA allowed Curis to enroll at least nine new patients at the 200mg dose level, while the hold remains for the combination and expansion phases. Curis also projects preliminary clinical data availability in 2023 as it works alongside the FDA on clinical plans for emavusertib.
Curis, Inc. (NASDAQ: CRIS) announced the U.S. FDA lifted the partial clinical hold on its TakeAim Lymphoma Phase 1/2 study of emavusertib. Following the FDA's review, Curis is preparing to resume patient enrollment in Q3 2022. The hold was lifted after agreement on the strategy for managing rhabdomyolysis. Curis will provide a preliminary clinical data update in 2023. The TakeAim Lymphoma study explores emavusertib's effectiveness in treating hematologic malignancies, while the TakeAim Leukemia study remains on hold since April 2022.
Curis, Inc. (CRIS) reported promising clinical results for emavusertib and ibrutinib at ASCO 2022, showing tumor reduction in 8 of 9 evaluable patients, highlighting potential in overcoming ibrutinib resistance. The company appointed Diantha Duvall as CFO, bringing extensive industry experience. For Q2 2022, Curis recorded a net loss of $15.9 million ($0.17/share), a rise from a $10.8 million loss in Q2 2021. Revenue remained stable at $2.4 million. With a strong balance sheet of $107.2 million, Curis is funded into 2024. A conference call is scheduled for today to discuss these results.
Curis, Inc. (NASDAQ: CRIS) announced on July 22, 2022, that its Compensation Committee approved an inducement stock option grant for 540,000 shares to a new employee, effective on the employee's hire date of July 26, 2022. The exercise price matches the stock's closing price on that date. The options have a 10-year term and vest over four years. Curis is engaged in developing cancer therapeutics, including collaborations for innovative treatments. Notably, the FDA has placed a partial clinical hold on certain trials due to safety concerns.
Curis, Inc. (NASDAQ: CRIS) will release its Q2 2022 financial results on August 4, 2022, after the close of U.S. markets. A conference call will be held on the same day at 4:30 pm ET to discuss the results. Investors can dial in or access the call on Curis's website. The company focuses on developing innovative cancer therapeutics, with ongoing trials for its drug emavusertib and partnerships with organizations like Aurigene and Genentech. The FDA has placed a partial clinical hold on certain trials but allows current participants to continue treatment.
Curis, Inc. (NASDAQ: CRIS) announced the grant of 873,750 inducement stock options to 16 new employees, effective July 5, 2022. Each option has an exercise price equal to the closing stock price on that date and vests over four years. This move aims to attract talent and is part of their strategy in developing innovative cancer therapeutics, including ongoing clinical trials for the IRAK4 inhibitor, emavusertib. Curis faces a partial clinical hold on its TakeAim trials, impacting new patient enrollment.
Curis, Inc. (NASDAQ: CRIS) presented novel findings at the 2022 European Hematology Association Congress regarding the IRAK4 inhibitor, emavusertib. The data suggest that nuclear localization of IRAK4 in cancer cells, particularly in acute myeloid leukemia (AML), correlates with better treatment responses. Notably, one patient with primary CNS lymphoma achieved a complete response following emavusertib treatment after prior ibrutinib therapy. The company aims to develop a companion diagnostic for identifying patients most likely to benefit from emavusertib, which is currently undergoing trials for various hematologic malignancies.
Curis, Inc. (NASDAQ: CRIS) presented positive clinical data for emavusertib at the 2022 ASCO Annual Meeting. In the TakeAim Lymphoma study, 8 of 9 evaluable patients achieved tumor reduction, including 2 complete and 2 partial responses. Notably, complete response was observed in a patient with prior ibrutinib treatment, suggesting potential for overcoming ibrutinib resistance. In the TakeAim Leukemia trial, emavusertib showed promising single-agent activity in heavily pretreated AML and HR-MDS patients. The trials are currently under partial clinical hold by the FDA.
Curis, a biotechnology firm listed under NASDAQ: CRIS, will present a company overview at the 2022 Jefferies Healthcare Conference on June 9, 2022, at 11:00 a.m. in New York. James Dentzer, President and CEO, will lead the presentation. A live webcast will be available on the Curis website, with a replay accessible for 90 days post-event. Curis focuses on cancer therapeutics, holding licenses for various innovative treatments, including emavusertib, currently in clinical trials, despite a partial hold by the FDA on certain trials. For more details, visit www.curis.com.
Curis (NASDAQ: CRIS) announces the upcoming presentations of multiple abstracts at the European Hematology Association 2022 Hybrid Congress from June 9-12, 2022, in Vienna. Key data from the TakeAim Lymphoma trial shows early anti-cancer activity with emavusertib combined with ibrutinib in heavily pretreated patients, including one complete response and two partial responses. Additionally, relevant insights from the TakeAim Leukemia study will also be shared. The company highlights the need for new treatment options for patients with resistant hematologic cancers.
FAQ
What is the current stock price of Curis (CRIS)?
What is the market cap of Curis (CRIS)?
What is Curis Inc.'s focus in the biotechnology sector?
What are some of the key drug candidates in Curis's pipeline?
What significant collaborations does Curis have?
What is the current status of Emavusertib's clinical trials?
How is Curis performing financially?
What recent achievements has Curis reported?
What is the significance of Curis's collaboration with Aurigene?
What role does Genentech play in Curis's portfolio?
What are Curis's future plans for its drug pipeline?
Where can I find more information about Curis Inc.?
